PMID- 33777797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Circulating Genetically Abnormal Cells Add Non-Invasive Diagnosis Value to 
      Discriminate Lung Cancer in Patients With Pulmonary Nodules </=10 mm.
PG  - 638223
LID - 10.3389/fonc.2021.638223 [doi]
LID - 638223
AB  - BACKGROUND: Lung cancer screening using low-dose computed tomography (LDCT) often 
      leads to unnecessary biopsy because of the low specificity among patients with 
      pulmonary nodules </=10 mm. Circulating genetically abnormal cells (CACs) can be 
      used to discriminate lung cancer from benign lung disease. To examine the 
      diagnostic value of CACs in detecting lung cancer for patients with malignant 
      pulmonary nodules </=10 mm. METHODS: In this prospective study, patients with 
      pulmonary nodules </=10 mm who were detected at four hospitals in China from 
      January 2019 to January 2020 were included. CACs were detected using fluorescence 
      in-situ hybridization. All patients were confirmed as lung cancer or benign 
      disease by further histopathological examination. Multivariable logistic 
      regression models were established to detect the presence of lung cancer using 
      CACs and other associated characteristics. Receiver operating characteristic 
      analysis was used to evaluate the performance of CACs for lung cancer diagnosis. 
      RESULTS: Overall, 125 patients were included and analyzed. When the cutoff value 
      of CACs was >2, the sensitivity and specificity for lung cancer were 70.5 and 
      86.4%. Male (OR = 0.330, P = 0.005), maximum solid nodule (OR = 2.362, P = 
      0.089), maximum nodule located in upper lobe (OR = 3.867, P = 0.001), and CACs >2 
      (OR = 18.525, P < 0.001) met the P < 0.10 criterion for inclusion in the 
      multivariable models. The multivariable logistic regression model that included 
      the dichotomized CACs (>2 vs. </=2) and other clinical factors (AUC = 0.907, 95% CI 
      = 0.842-0.951) was superior to the models that only considered dichotomized CACs 
      or other clinical factors and similar to the model with numerical CACs and other 
      clinical factors (AUC = 0.913, 95% CI = 0.850-0.956). CONCLUSION: CACs presented 
      a significant diagnostic value in detecting lung cancer for patients with 
      pulmonary nodules </=10 mm.
CI  - Copyright (c) 2021 Ye, Zheng, Ye, Zhang, Huang, Liu, Huang, Fan, Chen, Xiao, Sun 
      and Bai.
FAU - Ye, Maosong
AU  - Ye M
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zheng, Xiaoxuan
AU  - Zheng X
AD  - Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai, China.
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University, Shanghai, China.
FAU - Ye, Xin
AU  - Ye X
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong Kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
AD  - School of Biology and Biological Engineering, South China University of 
      Technology, Guangzhou, China.
FAU - Zhang, Juncheng
AU  - Zhang J
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong Kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Huang, Chuoji
AU  - Huang C
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong Kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Liu, Zilong
AU  - Liu Z
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Huang, Meng
AU  - Huang M
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong Kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Fan, Xianjun
AU  - Fan X
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong Kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Chen, Yanci
AU  - Chen Y
AD  - Joint Research Center of Liquid Biopsy in Guangdong, Hong Kong, and Macao, 
      Zhuhai, China.
AD  - Zhuhai Sanmed Biotech Ltd., Zhuhai, China.
FAU - Xiao, Botao
AU  - Xiao B
AD  - School of Biology and Biological Engineering, South China University of 
      Technology, Guangzhou, China.
FAU - Sun, Jiayuan
AU  - Sun J
AD  - Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai, China.
AD  - Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, 
      Shanghai Jiao Tong University, Shanghai, China.
FAU - Bai, Chunxue
AU  - Bai C
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210311
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7991838
OTO - NOTNLM
OT  - circulating genetically abnormal cell (CAC)
OT  - early detection
OT  - early diagnosis
OT  - lung cancer
OT  - pulmonary nodule
COIS- XY, JZ, CH, MH, XF and YC was employed by Zhuhai Sanmed Biotech Ltd. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/30 06:00
MHDA- 2021/03/30 06:01
PMCR- 2021/01/01
CRDT- 2021/03/29 06:35
PHST- 2020/12/05 00:00 [received]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/03/29 06:35 [entrez]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/03/30 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.638223 [doi]
PST - epublish
SO  - Front Oncol. 2021 Mar 11;11:638223. doi: 10.3389/fonc.2021.638223. eCollection 
      2021.